ENTRY       D10104                      Drug
NAME        Dabrafenib mesylate (USAN);
            Dabrafenib mesilate (JAN);
            Tafinlar (TN)
PRODUCT     TAFINLAR (Novartis Pharmaceuticals Corporation)
FORMULA     C23H20F3N5O2S2. CH4SO3
EXACT_MASS  615.0892
MOL_WEIGHT  615.6681
CLASS       Antineoplastic
             DG03159  BRAF inhibitor
            Metabolizing enzyme substrate
             DG02918  CYP2C8 substrate
             DG01633  CYP3A/CYP3A4 substrate
              DG02913  CYP3A4 substrate
            Metabolizing enzyme inducer
             DG02886  CYP2C9 inducer
             DG02853  CYP3A/CYP3A4 inducer
              DG01635  CYP3A4 inducer
REMARK      Therapeutic category: 4291
            ATC code: L01EC02
            Chemical structure group: DG00721
            Product (DG00721): D10104<JP/US>
EFFICACY    Antineoplastic, BRAF kinase inhibitor
  DISEASE   Melanoma (BRAF mutation positive) [DS:H00038]
            Non-small cell lung cancer (BRAF mutation positive) [DS:H00014]
            Anaplastic thyroid cancer (BRAF mutation positive) [DS:H00032]
TARGET      BRAF* [HSA_VAR:673v1] [HSA:673] [KO:K04365]
  PATHWAY   hsa04010(673)  MAPK signaling pathway
            hsa04012(673)  ErbB signaling pathway
            hsa05200(673)  Pathways in cancer
            hsa05218(673)  Melanoma
METABOLISM  Enzyme: CYP3A4 [HSA:1576], CYP2C8 [HSA:1558]
INTERACTION CYP induction: CYP3A4 [HSA:1576], CYP2C9 [HSA:1559]
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
              L01 ANTINEOPLASTIC AGENTS
               L01E PROTEIN KINASE INHIBITORS
                L01EC B-Raf serine-threonine kinase (BRAF) inhibitors
                 L01EC02 Dabrafenib
                  D10104  Dabrafenib mesylate (USAN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Antineoplastics
              Molecular Target Inhibitors
               Dabrafenib
                D10104  Dabrafenib mesylate (USAN)
            Therapeutic category of drugs in Japan [BR:br08301]
             4  Agents affecting cellular function
              42  Antineoplastics
               429  Miscellaneous
                4291  Other Antitumors
                 D10104  Dabrafenib mesylate (USAN); Dabrafenib mesilate (JAN)
            Drug groups [BR:br08330]
             Antineoplastic
              DG03159  BRAF inhibitor
               DG00721  Dabrafenib
                D10104  Dabrafenib mesylate
             Metabolizing enzyme substrate
              DG02918  CYP2C8 substrate
               DG00721  Dabrafenib
                D10104  Dabrafenib mesylate
              DG01633  CYP3A/CYP3A4 substrate
               DG02913  CYP3A4 substrate
                DG00721  Dabrafenib
                 D10104  Dabrafenib mesylate
             Metabolizing enzyme inducer
              DG02886  CYP2C9 inducer
               DG00721  Dabrafenib
                D10104  Dabrafenib mesylate
              DG02853  CYP3A/CYP3A4 inducer
               DG01635  CYP3A4 inducer
                DG00721  Dabrafenib
                 D10104  Dabrafenib mesylate
            Drug classes [BR:br08332]
             Antineoplastic
              DG03159  BRAF inhibitor
               D10104  Dabrafenib mesylate
            Target-based classification of drugs [BR:br08310]
             Protein kinases
              Serine/threonine kinases
               TKL group
                BRAF* [HSA_VAR:673v1]
                 D10104  Dabrafenib mesylate (USAN) &lt;JP/US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D10104
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D10104
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D10104
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D10104
            Drug metabolizing enzymes and transporters [br08309.html]
             Drug metabolizing enzymes
              D10104
            Pharmacogenomic biomarkers [br08341.html]
             Somatic variations in targeted cancer therapies
              D10104
            Drug groups [BR:br08330]
             Antineoplastic
              DG03159  BRAF inhibitor
               DG00721  Dabrafenib
             Metabolizing enzyme substrate
              DG02918  CYP2C8 substrate
               DG00721  Dabrafenib
              DG01633  CYP3A/CYP3A4 substrate
               DG02913  CYP3A4 substrate
                DG00721  Dabrafenib
             Metabolizing enzyme inducer
              DG02886  CYP2C9 inducer
               DG00721  Dabrafenib
              DG02853  CYP3A/CYP3A4 inducer
               DG01635  CYP3A4 inducer
                DG00721  Dabrafenib
DBLINKS     CAS: 1195768-06-9
            PubChem: 135626822
            ChEBI: 75048
            LigandBox: D10104
ATOM        40
            1   C8y C    29.4000  -20.0900
            2   C8y C    29.4000  -21.4900
            3   C8x C    30.5900  -22.1900
            4   C8x C    31.8500  -21.4900
            5   C8x C    31.8500  -20.0900
            6   C8y C    30.5900  -19.3900
            7   X   F    30.5900  -17.9900
            8   X   F    28.2100  -22.1900
            9   S4a S    28.2100  -19.3900
            10  N1b N    26.9500  -20.0900
            11  C8y C    25.7600  -19.3900
            12  C8x C    25.7600  -17.9900
            13  C8x C    24.5700  -17.2900
            14  C8x C    23.3800  -17.9900
            15  C8y C    23.3800  -19.3900
            16  C8y C    24.5700  -20.0900
            17  X   F    24.5700  -21.4900
            18  C8y C    22.1200  -20.0900
            19  N5x N    21.0000  -19.3200
            20  C8y C    19.8800  -20.0900
            21  S2x S    20.3700  -21.4200
            22  C8y C    21.7000  -21.4200
            23  C8y C    22.6100  -22.5400
            24  C8x C    21.8400  -23.7300
            25  C8x C    22.5400  -24.9900
            26  N5x N    23.9400  -24.9900
            27  C8y C    24.6400  -23.8000
            28  N5x N    24.0100  -22.5400
            29  C1d C    18.5500  -19.7400
            30  C1a C    17.5700  -20.6500
            31  C1a C    18.2700  -18.3400
            32  C1a C    17.2200  -19.3200
            33  N1a N    26.1100  -23.8700
            34  O1d O    27.1600  -18.4100
            35  O1d O    29.1900  -18.4100
            36  S4a S    35.7000  -20.6500
            37  O1d O    35.7000  -19.2500
            38  O1d O    35.7000  -22.0500
            39  O1d O    37.1000  -20.6500
            40  C1a C    34.3000  -20.6500
BOND        42
            1     1   2 2
            2     2   3 1
            3     3   4 2
            4     4   5 1
            5     5   6 2
            6     1   6 1
            7     6   7 1
            8     2   8 1
            9     1   9 1
            10    9  10 1
            11   10  11 1
            12   11  12 2
            13   12  13 1
            14   13  14 2
            15   14  15 1
            16   15  16 2
            17   11  16 1
            18   16  17 1
            19   15  18 1
            20   18  19 1
            21   19  20 2
            22   20  21 1
            23   21  22 1
            24   18  22 2
            25   22  23 1
            26   23  24 1
            27   24  25 2
            28   25  26 1
            29   26  27 2
            30   27  28 1
            31   23  28 2
            32   20  29 1
            33   29  30 1
            34   29  31 1
            35   29  32 1
            36   27  33 1
            37    9  34 2
            38    9  35 2
            39   36  37 2
            40   36  38 2
            41   36  39 1
            42   36  40 1
///
